Cardlytics, Inc. (NASDAQ:CDLX) Receives Consensus Rating of “Hold” from Brokerages

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have been given a consensus rating of “Hold” by the eight brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $132.17.

A number of research firms recently issued reports on CDLX. Zacks Investment Research lowered Cardlytics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 10th. JPMorgan Chase & Co. boosted their price target on Cardlytics from $110.00 to $130.00 and gave the company a “neutral” rating in a report on Monday, March 22nd. Craig Hallum boosted their price target on Cardlytics from $145.00 to $160.00 and gave the company a “buy” rating in a report on Wednesday, May 5th. Wells Fargo & Company upgraded Cardlytics from an “equal weight” rating to an “overweight” rating and set a $150.00 price target for the company in a report on Wednesday, April 21st. Finally, Truist boosted their price target on Cardlytics from $90.00 to $150.00 in a report on Monday, March 1st.

In other news, CEO Lynne Marie Laube sold 9,053 shares of the company’s stock in a transaction on Friday, May 7th. The stock was sold at an average price of $102.03, for a total transaction of $923,677.59. Following the completion of the sale, the chief executive officer now directly owns 315,714 shares in the company, valued at approximately $32,212,299.42. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Kirk Somers sold 5,032 shares of the company’s stock in a transaction on Monday, May 10th. The stock was sold at an average price of $98.23, for a total value of $494,293.36. Following the sale, the insider now owns 28,364 shares of the company’s stock, valued at $2,786,195.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 64,334 shares of company stock valued at $7,370,350. Insiders own 6.50% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Skye Global Management LP acquired a new stake in Cardlytics in the 1st quarter valued at $241,000. XTX Topco Ltd acquired a new stake in Cardlytics in the 1st quarter valued at $559,000. UBS Asset Management Americas Inc. increased its holdings in Cardlytics by 10.2% in the 1st quarter. UBS Asset Management Americas Inc. now owns 32,513 shares of the company’s stock valued at $3,567,000 after purchasing an additional 3,010 shares in the last quarter. Nicholas Investment Partners LP increased its holdings in Cardlytics by 7.9% in the 1st quarter. Nicholas Investment Partners LP now owns 64,988 shares of the company’s stock valued at $7,129,000 after purchasing an additional 4,777 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Cardlytics in the 1st quarter valued at $812,000. Institutional investors and hedge funds own 97.03% of the company’s stock.

CDLX stock traded up $3.98 on Tuesday, reaching $92.34. The company had a trading volume of 606,376 shares, compared to its average volume of 495,803. Cardlytics has a 1 year low of $51.15 and a 1 year high of $161.47. The company has a debt-to-equity ratio of 1.14, a quick ratio of 6.08 and a current ratio of 6.08. The company’s fifty day moving average is $117.13 and its 200 day moving average is $124.66. The company has a market cap of $3.04 billion, a P/E ratio of -54.96 and a beta of 2.63.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Tuesday, May 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.22. Cardlytics had a negative return on equity of 31.98% and a negative net margin of 23.91%. The firm had revenue of $53.00 million for the quarter, compared to analyst estimates of $51.96 million. During the same quarter in the prior year, the company earned ($0.26) EPS. Cardlytics’s revenue was up 16.5% on a year-over-year basis. On average, sell-side analysts predict that Cardlytics will post -2.08 earnings per share for the current year.

About Cardlytics

Cardlytics, Inc operates an advertising platform within financial institutions digital channels that include online, mobile, email, and various real-time notifications in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Read More: Why are percentage decliners important?

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.